Two peptides come up together constantly in discussions of focus and stress, and almost nobody explains why they are related. Semax and selank are not similar because they do similar things. They are similar because they were built by the same people, in the same laboratory, using the same structural trick.
Both came out of the Institute of Molecular Genetics in Moscow. Both take a naturally occurring fragment of a larger human molecule and bolt the same three amino acids onto the end of it to stop enzymes chewing it up. They then go on to do fairly different things. This covers what the semax research actually reports, how it differs from selank, and why the evidence base for both comes with an asterisk most articles skip.
What is semax, and what the Pro-Gly-Pro trick does
Semax is a seven-amino-acid peptide. The first four residues correspond to fragment 4 through 7 of adrenocorticotropic hormone, or ACTH. The last three are proline, glycine, proline.
ACTH is the hormone that tells the adrenal glands to produce cortisol, which sounds like exactly the sort of thing you would not want to stimulate. The relevant discovery, made decades ago, is that ACTH’s effects on the brain and its hormonal effects on the adrenal glands live in different parts of the molecule. The fragment semax is built from carries the neurological activity and none of the corticotropic activity. It does not raise cortisol.
The Pro-Gly-Pro tail is a stability modification, and it is the same one used in selank. Native peptide fragments are degraded in minutes by peptidases. That proline-heavy tail resists cleavage, so the molecule survives long enough to do something measurable. It is a small piece of protein engineering and it is the reason both compounds exist in usable form rather than as interesting fragments that disappear on contact with plasma.
Semax peptide benefits: what the research reports
The mechanism most consistently described in the literature is an effect on BDNF, brain-derived neurotrophic factor. BDNF supports the survival of existing neurons and the growth of new connections between them, and it is one of the more heavily studied molecules in neuroscience for that reason.
Studies report that semax increases BDNF expression along with its receptor TrkB, particularly in the hippocampus. Additional work describes effects on dopaminergic and serotonergic signaling, and on the brain’s response to reduced blood flow.
The clinical research is dominated by stroke. Semax is registered in Russia for ischemic stroke and for certain optic nerve conditions, and the trials supporting that registration examined neurological recovery in the period after an ischemic event. Additional Russian work covers cognitive function and attention in healthy subjects.
Two things about that body of evidence deserve stating plainly. It is overwhelmingly Russian-language, published in journals with limited international indexing, and much of it predates modern trial reporting standards. And it has not been meaningfully replicated by independent groups outside Russia. That is not evidence the findings are wrong. It is a reason the compound has a registration in one country and no regulatory standing anywhere else, and it is the single most important thing to understand before reading any confident claim about what semax does.
Semax and selank: how the two compounds differ
Selank shares the engineering and not the parent molecule. Where semax is built from an ACTH fragment, selank is built from tuftsin, a four-amino-acid immune-signaling peptide, with the same Pro-Gly-Pro tail attached.
That different starting point produces a different profile.
| Semax | Selank | |
|---|---|---|
| Derived from | ACTH fragment 4-7 | Tuftsin |
| Length | 7 amino acids | 7 amino acids |
| Primary studied effect | Cognition, neuroprotection | Anxiety, stress response |
| Main reported mechanism | BDNF and TrkB upregulation | GABA-A modulation, serotonin metabolism |
| Russian registration | Ischemic stroke, optic nerve conditions | Anxiety disorders |
| Sedation reported | No | No |
| Stocked at Healio | No | Yes |
The useful way to hold the distinction: semax research is aimed at the machinery of cognition and neuronal survival, selank research at the regulation of the stress response. They overlap at the edges, since anxiety degrades concentration and poor concentration generates anxiety, but the studies point in different directions.
Selank also kept something from its tuftsin parentage that semax has no equivalent of. Tuftsin is an immune peptide, and selank retains measurable immunomodulatory activity, with reported effects on interleukin-6 and interferon signaling. Whether that matters for the anxiety findings or is simply a leftover of the source molecule is unresolved.
Is semax a stimulant?
No. Semax does not act on the pathways stimulants act on. It does not block adenosine the way caffeine does, and it does not drive catecholamine release the way amphetamines do. The reported mechanism runs through neurotrophic signaling, specifically BDNF, which operates on a timescale of days rather than the immediate arousal a stimulant produces.
This distinction gets lost constantly, because semax is marketed inside the nootropics conversation where most of the other entries are stimulants or close relatives. A compound that upregulates a growth factor and a compound that borrows alertness from later in the day are not doing comparable things, whatever they are shelved next to.
Semax variants: why N-acetyl semax amidate is a different molecule
This is the detail that causes the most confusion in the semax market, and it is worth more than the passing mention it usually gets.
The compound studied in the Russian trials is plain semax. What circulates most widely through international research vendors is N-acetyl semax amidate, often abbreviated NASA, which has an acetyl group added at one end and an amide group at the other. Both modifications exist to slow enzymatic degradation further, on the same logic as the Pro-Gly-Pro tail.
The problem is that modifying a molecule changes it. A compound with a longer half-life is not the same compound at a higher dose; it has a different exposure profile, potentially different distribution, and no independent trial record of its own. The registration data, the stroke research, the BDNF findings, all of it was generated on the unmodified peptide.
Product listings routinely cite research on semax while selling the acetylated amidated variant. That is not necessarily deceptive, since most vendors appear not to have registered the distinction themselves, but it means anyone comparing research claims across suppliers may be comparing statements about two different molecules. Reading the certificate of analysis rather than the product name is the only way to know which one is in the vial.
A related note on why so much of the research used intranasal delivery: peptides do not cross the blood-brain barrier readily, and the nasal route offers a partial path along the olfactory and trigeminal nerves that bypasses it. The Russian studies were designed around that constraint. It is a fact about how the research was conducted, and it is worth knowing when reading findings that assume a delivery route.
Why Healio does not stock semax
Worth being direct, since this article covers a compound we do not sell.
The evidence base is the reason. Selank and semax have comparable Russian research histories, but selank’s anxiolytic work includes controlled comparisons against established benzodiazepines, which gives it a reference point that most of the semax literature lacks. Beyond that, the semax material circulating internationally comes in several variants, most commonly N-acetyl semax amidate, which is a chemically distinct molecule from the semax the Russian trials studied. Vendors routinely present research on one as though it applies to the other.
Stocking a compound where the most common commercial form is not the form that was studied is difficult to justify against the standard applied to everything else in the catalog. So it is not here, and saying so is more useful than quietly leaving the question open.
What semax and selank research does not cover
Neither compound has FDA approval or approval anywhere outside Russia and a small number of neighboring countries. Neither has been through the multi-phase trial process that Western regulators require.
Long-term safety data does not exist for either at any meaningful duration. The reported side effect profiles are mild, with nasal irritation from intranasal administration the most commonly noted, but a mild profile observed over short study periods is not the same as a characterized long-term profile.
There is also a specific question the BDNF findings raise and do not answer. Upregulating a growth factor is the mechanism the research is built on, and growth factors do not act only where you want them to. BDNF signaling has been examined in contexts well beyond cognition, and a compound that raises it persistently is doing something systemic. Short trials in stroke recovery, where the risk calculation is entirely different, tell you very little about sustained use in a healthy person. The literature has not addressed this, and the pages selling the compound do not raise it.
And the sex-representation problem that runs through most of this category runs through this corner of it as well. Anxiety disorders are diagnosed in women at roughly twice the rate they are in men, and both estrogen and progesterone influence GABA signaling directly, which is the system selank is described as acting on. Allopregnanolone, a progesterone metabolite, is itself a GABA-A modulator, and its levels swing across the menstrual cycle. A compound acting on that same receptor system in a body where the endogenous modulator is already fluctuating is a genuinely different research question from the one most of these studies were built to answer, and it has not been asked.
Sourcing selank and verifying what you receive
Both compounds are supplied by research vendors rather than pharmacies outside Russia, so documentation carries the entire weight of verification.
Check that the certificate of analysis names an independent laboratory unconnected to the vendor, that the batch number matches your vial, that purity is established by HPLC, and that identity is confirmed by mass spectrometry. Identity confirmation matters unusually much here, given how readily semax and its acetylated variants get treated as interchangeable in product listings.
Healio publishes every batch certificate openly at the research page, before purchase rather than on request afterward. Selank sits in the peptides for energy collection alongside the compounds studied against mitochondrial function, which address a different cause of the same complaint. Both arrive lyophilized, and the reconstitution guide covers solvent choice and stability.
Semax peptide benefits: frequently asked questions
What does semax do?
The research describes increased expression of BDNF and its receptor TrkB, along with effects on dopaminergic and serotonergic signaling. Clinical work in Russia focused on neurological recovery after ischemic stroke and on certain optic nerve conditions. It carries no corticotropic activity despite being derived from an ACTH fragment, so it does not raise cortisol.
Is semax FDA approved?
No. Semax has no FDA approval and no regulatory standing outside Russia and a small number of neighboring countries, where it is registered for ischemic stroke and optic nerve conditions. Material sold internationally is supplied as a research compound and is not the registered pharmaceutical product.
What is the difference between semax and selank?
Both are seven-amino-acid peptides from the same Russian institute, sharing a Pro-Gly-Pro stability tail. Semax derives from an ACTH fragment and is studied for cognition and neuroprotection via BDNF. Selank derives from tuftsin and is studied for anxiety via GABA-A modulation, retaining some immunomodulatory activity from its parent molecule.
Is semax a stimulant?
No. It does not block adenosine or drive catecholamine release, which are the mechanisms behind caffeine and amphetamine-class stimulants. Its described mechanism runs through neurotrophic signaling, which operates over days rather than producing immediate arousal. The compounds studied for cellular energy production work differently again.
Can semax and selank be studied together?
They are frequently discussed as a pair because they share an origin and address adjacent problems. No published trial has tested them in combination, so any account of a combined effect is inference from their separate profiles rather than a documented finding.
Related reading
- Best Peptides for Energy: why the mitochondrial compounds are a different category entirely
- Best Peptides for Women: the full picture, sorted by research goal
- How to Reconstitute Peptides: solvent choice, the concentration math, and stability
- Selank Peptide Benefits: the sibling compound, and the benzodiazepine comparison
Research use only. Every compound referenced on this page is supplied strictly for laboratory research. Nothing here is dosing guidance, and you will not find administration instructions anywhere on this site. These materials are not for human consumption, have not been evaluated by the FDA, and nothing here is medical advice. Consult a qualified healthcare professional for questions about your own health.